Search results for "Azone"

showing 10 items of 170 documents

Room temperature ionic liquids structure and its effect on the mononuclear rearrangement of heterocycles: an approach using thermodynamic parameters.

2006

The kinetics of the rearrangement of the Z-phenylhydrazone of 3-benzoyl-5-phenyl-1,2,4-oxadiazole (1) into the relevant 4-benzoylamino-2,5-diphenyl-1,2,3-triazole (2) induced by amines have been studied in five room-temperature ionic liquids (RTILs) at different temperatures. The kinetic data collected show that both cationic and anionic parts of RTILs significantly influence the reactivity of the title reaction. The calculated activation parameters allow us to advance hypotheses about the weak interactions operating in RTIL solutions.

OxadiazolesMolecular StructureOrganic ChemistryKineticsCationic polymerizationHydrazonesTemperatureIonic Liquidsionic liquids base catalysis MHR reactionTriazolesKinetic energyIonchemistry.chemical_compoundchemistryHeterocyclic CompoundsIonic liquidOrganic chemistryPhysical chemistryMoleculeThermodynamicsReactivity (chemistry)Amine gas treatingAminesThe Journal of organic chemistry
researchProduct

On the Rearrangement in Dioxane/Water of (Z)-Arylhydrazones of 5-Amino-3-benzoyl-1,2,4-oxadiazole into (2-Aryl-5-phenyl-2H-1,2,3-triazol-4-yl)ureas: …

2006

We have recently evidenced an interesting differential behavior in the reactivity in dioxane/water between the (Z)-2,4-dinitrophenylhydrazone (1a) and the (Z)-phenylhydrazone (1b) of 5-amino-3-benzoyl-1,2,4- oxadiazole. The former rearranges into the relevant triazole 2a only at pS+ > 4.5 while undergoing hydrolysis at high proton concentration (pS+ < 3.5); on the contrary, the latter rearranges into 2b in the whole pS+ range examined (0.1 e pS+ e 14.9). Thus, for a deeper understanding of these differences we have now collected kinetic data on the rearrangement in dioxane/water of a series of 3- or 4-substituted (Z)-phenylhydrazones (1c-l) of 5-amino-3-benzoyl-1,2,4-oxadiazole in a wide ra…

OxadiazolesMolecular StructureStereochemistryArylOrganic ChemistryHydrazonesTriazoleSubstituentWaterOxadiazolemononuclear rearrangement of heterocycles acid catalysis base catalysisTriazolesChemical synthesisMedicinal chemistryCatalysisDioxanesKineticschemistry.chemical_compoundAcid catalysischemistryThermodynamicsAmine gas treatingReactivity (chemistry)
researchProduct

No le digan loco a Bill. Sobre internalismo y externalismo de las razones para la acción

2011

En este trabajo analizaré dos concepciones de la racionalidad práctica – bien conocidas y debatidas en la literatura contemporánea – con el propósito de mostrar que una es superior a la otra. La primera concepción, que será la defendida en este trabajo, es una concepción denominada “formal” o “internalista”, mientras que la segunda podría denominarse “sustancial” o “externalista”. En particular, defenderé una concepción formal moderada, análoga a la de Bernard Williams, según la cual Juan tiene una razón para hacer X, si y sólo si hacer X representa un medio (considerado) suficiente para satisfacer un deseo que él tendría luego de haber realizado el procedimiento argumentativo racional. In …

Palabras llave: razón práctica internalismo de la razones Williams concepción humiana Keywords: practical rationality internalism Williams Humean conceptionSettore IUS/20 - Filosofia Del Diritto
researchProduct

The Blood–Brain Barrier as a Target in Traumatic Brain Injury Treatment

2014

Traumatic brain injury (TBI) is one of the most frequent causes of death in the young population. Several clinical trials have unsuccessfully focused on direct neuroprotective therapies. Recently immunotherapeutic strategies shifted into focus of translational research in acute CNS diseases. Cross-talk between activated microglia and blood–brain barrier (BBB) could initiate opening of the BBB and subsequent recruitment of systemic immune cells and mediators into the brain. Stabilization of the BBB after TBI could be a promising strategy to limit neuronal inflammation, secondary brain damage and acute neurodegeneration. This review provides an overview on the pathophysiology of TBI and brain…

Pathologymedicine.medical_specialtyTraumatic brain injuryPeroxisome Proliferator-Activated ReceptorsBrain EdemaInflammationBrain damageBlood–brain barrierNeuroprotectionRosiglitazoneReceptors GlucocorticoidmedicineHumansHypoglycemic AgentsMyosin-Light-Chain KinaseNeuroinflammationInflammationPioglitazoneMicrogliabusiness.industryNeurodegenerationNeurodegenerative DiseasesGeneral Medicinemedicine.diseaseCell HypoxiaNeuroprotective Agentsmedicine.anatomical_structurenervous systemBlood-Brain BarrierBrain InjuriesThiazolidinedionesmedicine.symptombusinessNeuroscienceArchives of Medical Research
researchProduct

Synthesis, X-ray structure, Hirshfeld analysis, and DFT studies of a new Pd(II) complex with an anionic s-triazine NNO donor ligand

2020

A new Pd(II) complex, [Pd(Triaz)Cl], with the hydrazono-s-triazine ligand, 2,4-di-tert-butyl-6-((2-(4-morpholino-6-(phenylamino)-1,3,5-triazin-2-yl)hydrazono)methyl)phenol, was synthesized by the reaction of PdCl2 with the organic ligand (1:1) in acetone under isothermal conditions. The molecular structure of the [Pd(Triaz)Cl] complex was determined using FTIR and 1H NMR spectroscopic techniques, and single-crystal X-ray diffraction. Moreover, using Hirshfeld surface analysis, the percentages of the intermolecular interactions were determined. The obtained values were 60.6%, 11.6%, 8.1%, 3.6%, and 5.0% for the H⋯H, C⋯H, O⋯H, N⋯H, and Cl⋯H interactions, respectively. Among them, the O⋯H, C⋯H…

Pd(II) complexs-triazinehydrazoneNBOHirshfeld surface analysismolekyylit
researchProduct

Zur Wirkung von Butazolidin auf Glutamins�ure-dehydrogenase und ?-Ketoglutarat-oxydase

1957

Glutamic dehydrogenase of rat liver mitochondria is inhibited by phenylbutazone at a final concentration of 2,5 mg-% (0,81 · 10−4 M). However, glutamic dehydrogenase in heart muscle homogenate and the cristalline enzyme from liver are not inhibited by phenylbutazone up to 10 mg-% (3,24 · 10−4 M), but they are inhibited by a metabolite arising during incubation of liver mitochondria with phenylbutazone.

Pharmacologychemistry.chemical_classificationRat liver mitochondriaMetabolitePharmacology toxicologyGeneral MedicineMitochondrionchemistry.chemical_compoundEnzymeBiochemistrychemistryPhenylbutazonemedicineGlutamic dehydrogenaseIncubationmedicine.drugNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Comparative enhancer effects of Span20 with Tween20 and Azone on the in vitro percutaneous penetration of compounds with different lipophilicities.

2000

Sorbitan monolaurate (Span20) was used in this study to analyze the influence of the polar functional group on the effects that non-ionic surfactants have on skin permeability. Its ethoxylate derivative polysorbate 20 (Tween20) and Azone, both with the same C12 alkyl chain as Span20, were used for comparative purposes. We evaluated the relative potency of the three molecules as enhancers in the permeability of a series of compounds with lipophilicities ranging from log Poct=-0.95 to log Poct=2.33. The influence of the enhancer concentration was also studied. For this purpose the epidermis of Wistar rat was pretreated with ethanolic solutions (1 and 5%, w/v) of each enhancer. Our results ind…

PolysorbateChromatographySkin AbsorptionPharmaceutical ScienceSorbitan monolaurateExcipientPolysorbatesAzepinesAdministration CutaneousDosage formRatschemistry.chemical_compoundSurface-Active AgentschemistryLipophilicitymedicineAnimalsPolysorbate 20Rats WistarEnhancerAzonemedicine.drugHexosesInternational journal of pharmaceutics
researchProduct

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

2011

OBJECTIVE To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. RESEARCH DESIGN AND METHODS The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test. Glycemic status was analyzed for the trial plus washout period and for the washout period alone. RESULTS Following median (interquartile range) 71 (63–86) days drug withdrawal, overall glycemic status remained modestly improved in t…

RamiprilAdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyPlaceboRosiglitazone03 medical and health sciencesDrug withdrawal0302 clinical medicineRamiprilInterquartile rangeInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsGlycemicOriginal ResearchAdvanced and Specialized Nursingbusiness.industryIncidence (epidemiology)IncidenceClinical Care/Education/Nutrition/Psychosocial ResearchMiddle Agedmedicine.disease3. Good healthSurgerySubstance Withdrawal SyndromeTreatment OutcomeDiabetes Mellitus Type 2FemaleThiazolidinedionesRosiglitazonebusinessmedicine.drugFollow-Up StudiesDiabetes Care
researchProduct

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.

2022

Guidelines have increasingly stressed the concept that adequate glycemic control is required to prevent or decrease the macro- and microvascular complications of type 2 diabetes mellitus (T2DM). PPAR-gamma agonists (“glitazones”) are no longer prioritized due to their effects on heart failure. However, the association between these drugs and innovative therapies could be a valuable tool to attenuate the risk factors of the metabolic syndrome. Glitazones are used for the treatment of diabetes and associated comorbidities. There is substantial scientific evidence demonstrating the effect of glitazones at a cardiometabolic level, as well as on hematological and neurological pathologies that po…

RosiglitazoneDiabetes Mellitus Type 2PioglitazonePeroxisome Proliferator-Activated ReceptorsHumansHypoglycemic AgentsThiazolidinedionescardiovascular risk metabolic syndrome pioglitazone type 2 diabetes mellitusGeneral MedicineMedicina (Kaunas, Lithuania)
researchProduct

Socs3 induction by PPARγ restrains cancer-promoting inflammation

2013

The presence of proinflammatory cytokines in the tumor microenvironment can support further growth of established cancers. Docosahexaenoic acid (DHA), a peroxisome proliferator-activated receptor-gamma (PPARγ) ligand, has been shown to suppress inflammation and limit tumor progression in vivo. Are the anticancer properties of DHA relying on its ability to prevent inflammation? If so, what are the molecular links between the anti-inflammatory properties of DHA and its anticancer effects? DHA is an n-3 polyinsaturated fatty acid mainly found in fish oil that was shown to contribute to inflammation resolution by preventing the release of proinflammatory mediators in vivo.1 DHA has also been as…

STAT3 Transcription FactorDocosahexaenoic AcidsCellular differentiationPeroxisome proliferator-activated receptorInflammationSuppressor of Cytokine Signaling ProteinsBiologyEditorials: Cell Cycle FeaturesProinflammatory cytokineMicemedicineAnimalsHumansPhosphorylationPromoter Regions GeneticMolecular BiologyCells Culturedchemistry.chemical_classificationInflammationTumor microenvironmentInterleukin-17TroglitazoneCell DifferentiationCell BiologyPPAR gammaCell Transformation NeoplasticchemistryGene Expression RegulationSuppressor of Cytokine Signaling 3 ProteinImmunologyCancer cellCancer researchTh17 CellsInterleukin 17medicine.symptomDevelopmental Biologymedicine.drugProtein BindingSignal TransductionCell Cycle
researchProduct